- Expires: December 28, 2022
- Credit: 1.00hr(s)
- CME
- Therapeutic Areas: Oncology, Urologic oncology
- Specialties: urothelial carcinoma (UC)
In this activity, an expert pathologist discusses the prognostic relevance of TP53 mutations, current diagnostic tools and principles for capturing TP53-mutated acute myeloid leukemia (AML), and new developments with innovative therapy for TP53-mutated AML.